{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.4","upperLimit":"94.6","value":"89.01"},{"groupId":"OG001","lowerLimit":"85.0","upperLimit":"96.0","value":"90.53"},{"groupId":"OG002","lowerLimit":"71.2","upperLimit":"84.9","value":"78.07"},{"groupId":"OG003","lowerLimit":"80.6","upperLimit":"92.4","value":"86.46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"185"},{"groupId":"OG003","value":"176"}],"units":"Participants"}],"description":"Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","dispersionType":"95% Confidence Interval","groups":[{"description":"No Nelarabine, Capizzi Methotrexate","id":"OG000","title":"ARM I (Combination Chemotherapy)"},{"description":"Nelarabine, Capizzi Methotrexate","id":"OG001","title":"ARM II (Combination Chemotherapy)"},{"description":"No Nelarabine, High-Dose Methotrexate","id":"OG002","title":"ARM III (Combination Chemotherapy)"},{"description":"Nelarabine, High-Dose Methotrexate","id":"OG003","title":"ARM IV (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Includes only T-cell Acute Lymphoblastic Leukemia (T-ALL) patients randomized to Nelarabine versus No Nelarabine. T-LLY patients are excluded from this analysis. Induction failures non-randomly assigned to Arm IV were excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"4 years from randomization at the end of induction","title":"Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)","type":"PRIMARY","unitOfMeasure":"percent probability"}